Abstract: The invention relates to a method of immunotherapy for prevention or treatment of cancer in a subject, the method comprising the administration of an adjuvant, or administration of an adjuvant in combination with a tumour antigen, to the subject, wherein the adjuvant comprises polyglucosamine or acetylated polyglucosamine that comprises no more than 10% N-acetyl-D-glucosamine groups, and wherein the N-acetyl-D-glucosamine groups are distributed in the acetylated polyglucosamine in blocks of two or more. The invention relates to a method of immunotherapy for solid-tumour cancer in a subject, the method comprising the administration of polyglucosamine or chitosan into the subject, wherein the administration is intratumoral and/or peritumoral.

Abstract: Provided by the current invention is a biocompatible polymeric particle having a diameter of from 50nm to 65nm and methods for use thereof. A method to induce antigen specific CD8 T cells and Thl response is also provided.

Abstract: The present invention provides compositions and methods for the suppression of Th2-mediated immune response. Tracheal cytotoxin is shown to mediate a selective suppression of T helper cell type 2 (Th2)-mediated immune responses. The methods and compositions of the invention are useful for the treatment of Th2-mediated diseases and conditions due to their utility in suppressing Th2-mediated immune responses. The invention further extends to methods for suppressing the production of cytokines, such as IL-4 and IL-5 which contribute to the development of Th2-mediated immune responses.